Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay
International Journal of Molecular Sciences · 29.04.2026 · 27 (9) · 3979
DOI: 10.3390/ijms27093979 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.04.2026. Verfasst von Scott Strum und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BMO Financial Chair in Precision Genomics.
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohort using a highly sensitive tumor-informed ctDNA assay. Participant samples were collected at the University Health Network across six study cohorts. A total of 273 patients with stage II-IV cancers spanning 16 tumor types were analyzed using a personalized tumor-informed assay (RaDaR®). Harmonized methods were employed to mitigate the impact of variables known to influence ctDNA detection and its quantification. Pre-treatment ctDNA was detected in 83% of participants (226/273) across all stages and cancer types. Detection rates varied by clinical characteristics, including cancer type and stage; ctDNA was detected in 100% of stage IV metastatic recurrent high-grade serous ovarian cancer (HGSOC) patients (n = 8/8) and 54% of stage IV melanoma patients (n = 6/11). The median estimated variant allele fraction (eVAF) across all patients with a positive ctDNA result was 0.25% (range: 0.000029–37.7%), varied by tumor type and increased with cancer stage. A total of 11% of positive samples (24/226) had an eVAF of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
- Department of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.
- NeoGenomics, Inc., Fort Myers, FL 33912, USA.
- Department of Oncology, Queen's School of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
ORCID-Profile: Scott Strum, Christopher G Smith, Anna Spreafico, Lillian L Siu, Mitchell Elliott, David W Cescon
Förderung
- BMO Financial Chair in Precision Genomics
Zitieren
APA
Strum, S., Murray, C., Genta, S., Sanz-Garcia, E., Razak, A., Lheureux, S., Pipinikas, C., Wang, B. X., Chevalier, A., Smith, C. G., Spreafico, A., Siu, L. L., Elliott, M., & Cescon, D. W. (2026). Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay. International Journal of Molecular Sciences, 27(9), 3979. https://doi.org/10.3390/ijms27093979
Vancouver
Strum S, Murray C, Genta S, Sanz-Garcia E, Razak A, Lheureux S, et al. Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay. International Journal of Molecular Sciences. 2026;27(9):3979. doi:10.3390/ijms27093979
BibTeX
@article{Strum2026,
author = {Strum, Scott and Murray, Clodagh and Genta, Sofia and Sanz-Garcia, Enrique and Razak, Albiruni and Lheureux, Stephanie and Pipinikas, Christodoulos and Wang, Ben X and Chevalier, Amber and Smith, Christopher G and Spreafico, Anna and Siu, Lillian L and Elliott, Mitchell and Cescon, David W},
title = {Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {9},
pages = {3979},
doi = {10.3390/ijms27093979}
}
EUVIMED